Global Wearable Injectors Market (2021 to 2026) – by Type, Technology, Application, End-user and Region

The “Wearable Injectors Market By Type, By Technology, By Application, By End-User, And By Regions – Global & Regional Industry Perspective, Comprehensive Analysis, and Forecast 2021 – 2026” report has been added to ResearchAndMarkets.com’s offering.

According to the report, the global wearable injectors market was valued at approximately USD 6.9 Billion in 2020 and is expected to reach a value of around USD 11.5 Billion by 2026, at a CAGR of around 8.9% between 2021 and 2026.

Wearable injectors are devices that can be worn on the body in the form of a patch or complete equipment for timely medicine inoculation. There are various kinds of medical condition in which timely injection of drugs are necessary for the normal functioning of the body when the person is affected from diabetes, Parkinson’s disease, heart disorders, and cancer. These products help the patient suffering from chronic diseases live a normal life. These devices can also be connected to the body in the form of a tube via a tiny discreet instrument. Moreover, wearable injectors also have wireless connectivity and their operations or functionalities can be regulated through software.

Rise in the occurrence of chronic ailments to drive the market expansion

The tremendous rise in the occurrence of chronic ailments like heart diseases, diabetes, and cancer will offer lucrative growth avenues for the market over the forecast timeline. According to the report of International Diabetes Federation, about 425 million persons were found be have been suffering from diabetes in 2017 and the figures are slated to hit nearly 629 million by 2045. Moreover, diabetic conditions need drug inoculation on time for maintaining normal body functioning. This will elevate the growth of the wearable injectors industry over the forecast timeline.

Furthermore, the launching of new technologies for maintaining the balance between disease management and lifestyles will further elevate the business growth during the forecast timeline. Moreover, technology has minimized the device size and made it user-friendly, thereby further accelerating the growth rate of the market over the forecast timeline. Nonetheless, growing acceptance of alternate modes of drug delivery will inhibit the scope of the market during the forecast timeframe.

On-body injectors to dominate the type segment by 2027

The users easily wear these devices and are handled by wireless connection & software. Moreover, technological breakthroughs have reduced the equipment size, thereby further steering the segmental growth over the forecast timeline.

Immuno-oncology segment to contribute majorly towards the overall market share by 2027

The growth of the segment during the forecast period is due to the high occurrence of cancer across the globe.

North America to lead the regional market growth during the period from 2019 to 2027

The growth of the market in North America is due to the presence of strong healthcare infrastructure along with growing incidences of chronic ailments. In addition to this, an increase in the research activities for biologics and the development of new injector design are a few of the major factors that are likely to steer the growth of the industry during the period from 2019 to 2027.

Furthermore, a rise in the acceptance of wearable injectors, favorable compensation policies, and bulge in healthcare spending are some of the aspects that will steer the regional market surge over the forecast timeline.

This report segments the Wearable Injectors market as follows:

Global Wearable Injectors Market: By Type Segment Analysis

  • On-Body
  • Off-Body

Global Wearable Injectors Market: By Technology Segment Analysis

  • Spring-Based
  • Motor-Driven
  • Rotary Pump
  • Expanding Battery
  • Others

Global Wearable Injectors Market: By Application Segment Analysis

  • Oncology
  • Infectious Diseases
  • Cardiovascular Diseases
  • Autoimmune Diseases
  • Others

Global Wearable Injectors Market: By End-User Segment Analysis

  • Hospitals
  • Clinic
  • Home Care Settings
  • Others

Global Wearable Injectors Market: Regional Segment Analysis

  • North America
  • U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa

Companies Mentioned

  • Becton
  • Dickinson and Company
  • Johnson & Johnson Services Inc.
  • F. Hoffman-La Roche Ltd.
  • Unilife Corporation
  • SteadyMed Therapeutics Inc.
  • Amgen Inc.
  • Insulet Corporation
  • Enable Injections
  • West Pharmaceuticals Services Inc.
  • CeQur S.A.
  • ATS Automation
  • Tandem Diabetes Care
  • Noble

For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”